Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 4/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4972916 | 1.00 | CTSK (0.52) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL4971022 | 0.91 | KYNU (0.57) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL28723315 | 0.87 | CTSK (0.50) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL28723314 | 0.87 | CTSK (0.50) | CTSKCTSSCTSLCTSBPPARA | |
| SCHEMBL24263442 | 0.87 | CTSK (0.50) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL7917484 | 0.85 | CA2 (0.52) | CTSKCTSSCTSLCTSB | |
| SCHEMBL2550717 | 0.85 | CA2 (0.52) | CTSKCTSSCTSLCTSB | |
| SCHEMBL2550712 | 0.85 | CA2 (0.52) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6947000 | 0.85 | SIRT2 (0.53) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL8671689 | 0.85 | SIRT2 (0.53) | CTSKCTSSCTSLCTSBITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023208005-A1 | CYCLIC COMPOUNDS, PREPARATION METHODS AND MEDICINAL USES THEREOF | HANSOH BIO LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-1236715-B1 | Process for S-Aryl cysteine | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-6765109-B1 | FORMATION OF ENANTIOSELECTIVE MATERIAL; REACTING ARYL THIOL AND PROTECTED SERINE DERIVATIVE | ROCHE COLORADO CORPORATION | 2004-07-20 | — | — | US | disclosed |
| EP-0968997-B1 | Process for S-aryl-L-cysteine and derivatives | HOFFMANN LA ROCHE (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-20020169337-A1 | Process for producing optically active cysteine derivatives | KANEKA CORPORATION (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-1236715-A2 | Process for S-Aryl cysteine | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-04 | — | — | EP | disclosed |
| US-6407281-B1 | ESTERIFICATION WITH ALCOHOL; SOLVENT EXTRACTION | KANEKA CORPORATION (JP) | 2002-06-18 | — | — | US | disclosed |
| US-6229041-B1 | COUPLING CYSTEINE WITH COPPER OR COPPER OXIDE TO GENERATE METAL-AMINO COMPLEX, THEN CONTACTING WITH ARYL-HALIDE TO PRODUCE 3-ARYL-CYSTEINE; XENOBIOTIC METABOLIC PATHWAYS; TARGETTING HIV VIRUS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-08 | — | — | US | disclosed |
| EP-1054000-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CYSTEINE DERIVATIVES | KANEKA CORPORATION (JP) | 2000-11-22 | — | — | EP | disclosed |
| EP-0968997-A2 | Process for S-aryl-L-cysteine and derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169337-A1 | Process for producing optically active cysteine derivatives | LANCL1, ACSL1, ACSL3 | CTSK 1261/4885CTSS 1995/4885CTSL 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.